Eagle Pharmaceuticals (EGRX)
(Delayed Data from NSDQ)
$5.62 USD
-0.43 (-7.11%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $5.65 +0.03 (0.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Eagle Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 317 | 172 | 188 | 196 |
Cost Of Goods | NA | 95 | 42 | 45 | 61 |
Gross Profit | NA | 222 | 129 | 142 | 135 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 141 | 127 | 109 | 113 |
Income After Depreciation & Amortization | 0 | 81 | 3 | 33 | 22 |
Non-Operating Income | NA | -15 | -6 | -8 | 3 |
Interest Expense | NA | 4 | 2 | 3 | 3 |
Pretax Income | NA | 61 | -5 | 23 | 22 |
Income Taxes | NA | 26 | 4 | 11 | 8 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 36 | -9 | 12 | 14 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 36 | -9 | 12 | 14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 95 | 8 | 38 | 27 |
Depreciation & Amortization (Cash Flow) | NA | 14 | 5 | 5 | 5 |
Income After Depreciation & Amortization | 0 | 81 | 3 | 33 | 22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 13.07 | 13.05 | 13.77 | 14.14 |
Diluted EPS Before Non-Recurring Items | NA | 2.73 | -0.66 | 0.87 | 1.38 |
Diluted Net EPS (GAAP) | NA | 2.73 | -0.66 | 0.87 | 1.01 |
Fiscal Year end for Eagle Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | NA | NA | 64.65 | 66.31 | 60.70 |
Cost Of Goods | NA | NA | 16.86 | 17.30 | 19.87 |
Gross Profit | NA | NA | 47.79 | 49.01 | 40.83 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 37.48 | 37.23 | 31.37 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 10.31 | 11.78 | 9.46 |
Non-Operating Income | NA | NA | 0.44 | -0.03 | 5.82 |
Interest Expense | NA | NA | 1.45 | 1.52 | 1.98 |
Pretax Income | NA | NA | 9.30 | 10.23 | 13.30 |
Income Taxes | NA | NA | 4.13 | 4.48 | 5.14 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | 5.16 | 5.75 | 8.17 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | 5.16 | 5.75 | 8.17 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | NA | NA | 13.16 | 13.15 | 13.12 |
Diluted EPS Before Non-Recurring Items | NA | NA | 0.39 | 0.44 | 0.62 |
Diluted Net EPS (GAAP) | NA | NA | 0.39 | 0.44 | 0.60 |